1.
Comparative Pharmacokinetics Of Silymarin In Healthy Male And Female Volunteers
by Farah Abid | Prof.Dr.Muhammad Ashraf | Dr. Mateen | Dr. Sualeha Riffat.
Material type: ; Format:
print
; Nature of contents: ; Literary form: Publisher: 2011Dissertation note: The study was designed to compare the pharmacokinetic parameters of Silymarin in 8
healthy male and 8 healthy female volunteers. Only those healthy volunteers were
selected who were of age between 18-45 years, not having any disease. Female's
volunteers were also of age of 18-45 years and also who were not pregnant and also not
suffering from any disease.
Written consent form were taken from the volunteer and they were thoroughly
inform about the study and objectives of study ,frequency of blood sampling, and any
other side effects linked to the drug which they might having during the study.
Volunteers were divided into two groups A and B respectively. Both groups
were given silymarin 200mg dose per oral to each individua1.5ml of blood samples were
drawn after different time interval .5 ,1,2,3,5,8 and 12 hr from the vein through 5ml BD
syringes of 22 gauge needle after oral administration of silymarin.
Plasma were separated by centrifugation at 5000 RPM and stored at -40 C till
analysis. Silymarin concentration in plasma was determined by using HPLC method. All
pharmacokinetics parameter were determined by entering the plasma concentration time
data in software APO pharmacological analysis .Then pharmacological parameters in
healthy male and healthy females were compared. Result showed that pharmacokinetic
parameters are significant & those parameters were AVC, Tmax, t1l2 & CI. This result
showed that there is a significant relationship between healthy male & female.
Availability: Items available for loan: UVAS Library [Call number: 1329,T] (1).
2.
Pharmacokinetics Of Carvedilol In Dogs After Oral Administration
by Khurram Wajih Mahmood | Ms. Huma Rasheed | Dr. Mateen | Dr. Sualeha Riffat.
Material type: ; Format:
print
; Literary form:
not fiction
Publisher: 2011Dissertation note: Carvedilol, is a class-II, non-biowaivered drug, with low solubility. It is a candidate for several in-vivo studies including bioavailability and bioequivalence of generic versus standard, and also for testing performance of modified release products. Single dose pharmacokinetic study was performed on 12 healthy dogs using 25mg Carvedilol tablets. The objective of this study was to perform pharmacokinetic and biopharmaceutic study in the dog model for Carvedilol. The animals were selected after screening by veterinary practitioner. Blood samples were collected after 15min, 30min, 1 hr, 1.5 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs, 12 hrs and 24 hrs via an in-dwelling catheter from the cephalic vein of the animals along with one base line sample taken before drug administration. The plasma samples obtained by centrifugation were analyzed by HPLC quantitative method after checking the reproducibility and linearity of the standard curve using the standards prepared in dog plasma. Pharmacokinetic parameters were calculated by using APO software, and using appropriate compartmental pharmacokinetic model. The data derived from this study was analyzed using descriptive statistics and the observed results were compared with the published literature. The pharmacokinetic parameters investigated show that peak plasma concentration was 72.33±32.84 ng/ml, elimination half life of 1.84±2.42 hrs, Mean Residence Time was 2.98±0.96hrs, Volume of distribution of 0.57±0.6 l/kg and time to peak plasma concentration of 1.77±0.31hrs. The study defends the older proposition by pharmacokineticists that the Carvedilol shows unpredictable absorption kinetics in dogs and a few of the parameters also relate with the published finding on the Carvedilol pharmacokinetics in human. The delay in absorption and significant lag time of 1.23hrs was consistent in all subjects. The study elaborated the prospects of the possibility of using animal studies to achieve predictable pharmacokinetics of the drugs without involving human subjects.
Availability: Items available for loan: UVAS Library [Call number: 1423,T] (1).
3.
Comparison Of Dsingle-Dose Pharmacokinetics Of Candesartan Cilexetil In Healthy Male & Female
by Hafiz Awais Nawaz | Muhammad Irfan Masood | Dr. Mateen | Dr. Sualeha Riffat.
Material type: ; Format:
print
; Literary form:
not fiction
Publisher: 2012Dissertation note: This study was designed to compare the pharmacokinetic parameters of Candesartan in 8 healthy male and female volunteers. The study was conducted in eight healthy male volunteers and eight healthy female volunteers. Only those male volunteers were selected who aged between 18-30 years, not suffering from any disease. Female volunteers were also between age of 18-30 years, who were not pregnant and not suffering from any disease. Written consent was taken from them and they were informed about objectives of the study, frequency of blood sampling, and possible side effects of drug which they might face during the study. The male volunteers were considered as group A and healthy female volunteers were considered as group B. Both groups were administered Candesartan 16mg tablet orally to each individual. 5ml Blood samples were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 & 72 hr after the oral drug administration from vein through 5ml B.D syringe of 22guage needle. Plasma was separated by centrifugation at 5000 RPM and stored at -80ºC till analysis. Candesartan concentrations in plasma were measured by HPLC method. All pharmacokinetic parameters were calculated by entering plasma concentration-time data in software APO pharmacological analysis MW/PHARM version 3.02 by assuming bio-availability of Candesartan after oral administration as 1. Pharmacokinetic parameters of Candesartan in healthy male and female volunteers were compared. Data was analyzed by unpaired t-test and it was observed that there is significant difference in AUC of Candesartan in healthy male and female volunteers after oral administration without any effect in Cmax, Tmax, volume of distribution, absorption rate constant or elimination half life. In general, candesartan produced comparable results in healthy male and female volunteers so there is no need of any dose adjustment during therapy in both genders.
Availability: Items available for loan: UVAS Library [Call number: 1442,T] (1).
